Recombinant varicella zoster virus glycoprotein e antigen for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 31 Mar 2026: Trial registered, NCT07502560
  2. 31 Mar 2026: Trial started, NCT07502560

The trials

NCT07502560: A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

State
Under way
Phase
Phase 4
People
33,609 planned
Started
31 Mar 2026
Primary completion
1 Apr 2030
Arms
Recombinant zoster vaccine Group
Results
None posted
  1. 31 Mar 2026: Trial registered
  2. 31 Mar 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as RZV vaccine, Recombinant Herpes Zoster Vaccine (Shingrix), Recombinant zoster vaccine, Shingrix.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.